Drug Development Consulting Holding ApS: Financial statements 2022
CVR: 42285722
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
Drug Development Consulting Holding ApS (CVR 42285722) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -58,000 and a net result of DKK -11,874,000. Equity in the 2022 report amounted to DKK 71,988,000. The solvency ratio was 100%. The company had 184 employees in the financial year.
- Gross Profit
- DKK -58,000
- Profit/Loss
- DKK -11,874,000
- Equity
- DKK 71,988,000
- Total Assets
- DKK 72,021,000
- Employees
- 184
Official annual report
Keep an eye on Drug Development Consulting Holding ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
As of December 22, 2022, Alejandra Maria Cristina Bonifacini Mørk has joined the board of directors of Drug Development Consulting Holding ApS.
As of December 22, 2022, DDC Mørk Holding ApS is registered as an owner of Drug Development Consulting Holding ApS with an ownership share of 15%.
Drug Development Consulting Holding ApS has published its interim report for the period April 7, 2021 to December 31, 2021.
About Drug Development Consulting Holding ApS
Drug Development Consulting Holding ApS is a Danish company of the type Anpartsselskab based in Brøndby, founded in 2021. The company is registered under the industry Ikke-finansielle holdingselskaber. The management consists of René Holmen Pedersen. The board consists of Niels Peder Nielsen (chair), Alejandra Maria Cristina Bonifacini Mørk, Rafael Natanek and Redmar Koene. The company is owned by DDC Mørk Holding ApS and GHS III Midco B.V.. According to the 2025 annual report, the company had an average of 122 employees. In 2025, the company reported a gross profit of DKK -92,000 and a net result of DKK -61,449,000 compared with DKK -13,302,000 the year before. Equity in the 2025 report amounted to DKK 32,586,000.